Document is current
Any future updates will be listed below
-
Authors
Lupidi, Marco https://orcid.org/0000-0002-6817-2488
Iaculli, Cristiana https://orcid.org/0000-0003-0078-6480
Marco, Luisa
Rossi, Settimio https://orcid.org/0000-0002-8682-6860
Sicari, Emilia
Villa, Giulia
Pirani, Vittorio https://orcid.org/0000-0001-5760-5607
-
Funding
Funding for this research was provided by:
Roche Italia
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 30 June 2025
First Online: 19 July 2025
Declarations
:
: Marco Lupidi—Abbvie, Apellis, Bayer, Novartis, Heidelberg Engineering, Lumibrid, and Roche. Cristiana Iaculli—Roche and Bayer. Luisa Marco, Emilia Sicari, and Giulia Villa are Roche employees. Settimio Rossi and Vittorio Pirani declare that they have no competing interests.
: The research and data handling were conducted in compliance with the national legislation on observational studies [], the Principles of Good Practice [, ], and the tenets of the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of Regione Marche-CERM (protocol no. 2024/29), which served as the coordinating committee, and was subsequently approved by the ethics committees of all participating centers (details provided in Supplementary Material Table ). The study was also registered in the AIFA Observational Study Register (RSO) (study ID 1045). Written consent was obtained from all patients prior to enrollment and data collection.
